A randomized comparative trial in order to assess the reactogenicity and immunogenicity of a new measles mumps rubella (MMR) vaccine when given as a first dose at 12-24 months of age

Southeast Asian Journal of Tropical Medicine and Public Health

Volumn 30, Issue 3, 1999, Pages 511-517

  Gatchalian, Salvacion ^a   Cordero Yap, Leticia ^b   Lu Fong, Margaret ^c   Soriano, Rosalinda ^d   Ludan, Arturo ^e   Chitour, Kerim ^f   Bock, Hans L ^f  

^a UNIVERSITY OF THE PHILIPPINES MANILA   (Philippines)

^b Holy Child Clinic   (Philippines)

^c Cardinal Santos Medical Center   (Philippines)

^d Mary Johnston Hospital   (Philippines)

^e Captitol Medical Center   (Philippines)

^f GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

MEASLES MUMPS RUBELLA VACCINE; MEASLES VACCINE; MUMPS VACCINE; RUBELLA VACCINE; VACCINE;

ANALYSIS OF VARIANCE; ANTIBODY PRODUCTION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; HUMAN; IMMUNOLOGY; INFANT; MALE; MEASLES; MUMPS; PHILIPPINES; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; RUBELLA; SEIZURE;

ANALYSIS OF VARIANCE; ANTIBODY FORMATION; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; HUMANS; INFANT; MALE; MEASLES; MEASLES VACCINE; MEASLES-MUMPS-RUBELLA VACCINE; MUMPS; MUMPS VACCINE; PHILIPPINES; RUBELLA; RUBELLA VACCINE; SEIZURES; VACCINES, COMBINED;

EID: 0033186554     PISSN: 01251562     EISSN: 26975718     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Advisory Committee on Immunization Practices (ACIP). Measles, Mumps and Rubella - Vaccine use and strategies for elimination of measles, rubella and congenital rubella syndrome and control of mumps. MMWR 1998; 47: 1-49.
2. Afzal MA. Pickford AR. Forsey T. Heath AB, Minor PD. The Jeryl Lynn vaccine strain of mumps virus is a mixture of two distinct isolates. J Gen Virol 1993; 74: 917-20.
3. American Academy of Pediatrics (AAP): Committee on Infectious Disease. Age for routine administration of the second dose of measles-mumps-rubella vaccine. Pediatrics 1998; 101: 129-33.
4. Anderson RM, May RM. Immunisation and herd immunity: A Lancet review, Modern vaccines, Current practice and new approaches. Arnold E, ed. Lancet 1990; 335: 24-33.
5. Balraj V, Miller E. Complications of mumps vaccines. Rev Med Virol 1995; 5: 219-27.
6. Centers for Disease Control and Prevention (CDC). Reported vaccine-preventable diseases: United States, 1993, and the Childhood Immunization Initiative. MMWR 1994; 43: 57-60.
7. Chen RT, Markowitz LE, Albrecht P, et al. Measles antibody: reevaluation of protective titers. J Infect Dis 1990; 162: 1036-42.
8. Christenson B, Bottiger M. Methods for screening the naturally acquired and vaccine-induced immunity to the mumps virus. Biologicals 1990; 18: 213-9.
9. Cochi SL, Wharton M, Plotkin SA. Mumps Vaccine. In: Plotkin SA, Mortimer EA, eds. Vaccines. Philadelphia: Saunders, 1994: pp 277-301.
10. Fescharek R, Quast U, Maass G, Merkle W, Schwarz S. Measles-mumps vaccination in the FRG: an empirical analysis after 14 years of use. II. Tolerability and analysis of spontaneous reported side effects. Vaccine 1990; 8: 446-56.
11. Goldenthal KL, Burns DL, McVittie LD, Lewis BP Jr, Williams JC. Overview - Combination vaccines and simultaneous administration. In: Williams JC, Goldenthal KL, Burns DL, Lewis BP Jr, eds, Combined vaccines and simultaneous administration. Current issues and perspectives. Ann NY Acad Sci 1995; 754: XI-XV.
12. Hilleman MR. The development of live attenuated mumps virus vaccine in historic perspective and its role in the evolution of combined measles-mumps-rubella. In: Plotkin SA, Fantini B, eds. Vaccinia, vaccination and vaccinology: Jenner, Pasteur and their successors. Paris: Elsevier, 1996: pp 283-92.
13. Hilleman MR, Stokes J, Buynak EB, Weibel R, Halenda R, Goldner H. Enders' live measles-virus vaccine with human immune globulin. Am J Dis Child 1962; 103: 372-9.
14. Hilleman MR, Weibel RE, Buynak EB, Stokes J, Whitman JE. Live attenuated mumps-virus vaccine. N Engl J Med 1967; 276: 252-8.
15. Johnson H. Hillary IB, McQuoid G, Gilmer BA. MMR vaccination, measles epidemiology and sero-surveillance in the Republic of Ireland. Vaccine 1995; 13: 553-7.
16. Kimura M, Kuno-Sakai H, Yamazaki S, et al. Adverse events associated with MMR vaccines in Japan. Acta Paediatr Japonica 1996; 38: 205-11.
17. Kleiman MB, Blackburn CKL, Zimmerman SE, French MLV. Comparison of enzyme-linked immunosorbent assay for acute measles with hemagglutination inhibition, complement fixation and fluorescent-antibody methods. J Clin Microbiol 1981; 14: 147-52.
18. Krugman S, Giles JP, Friedman H, Stone S. Studies on immunity to measles. J Pediatr 1965; 66: 471-88.
19. Leinikki P, Shekarchi I, Tzan N, Madden DL, Sever JL. Evaluation of enzyme-linked immunosorbent assay (ELISA) for mumps virus antibodies (40451). Proc Soc Exp Biol Med 1979; 160: 363-7.
20. Markowitz LE, Katz SL. Measles vaccine In: Plotkin SA, Mortimer EA, eds. Vaccines. Philadelphia: Saunders, 1994: pp 229-60.
21. Miller E, Goldacre M, Pugh S, et al. Risk of aseptic meningitis after measles, mumps and rubella vaccine in UK children. Lancet 1993; 341: 979-82.
22. Miller E, Hill A, Morgan-Capner P, Forsey T, Rush M. Antibodies to measles, mumps and rubella in UK children 4 years after the vaccination with different MMR vaccines. Vaccine 1995; 13: 799-802.
23. Neumann PW, Weber JM, Jessamine AG, O'Shaughnessy M. Comparison of measles antihemolysin test, enzyme-linked immunosorbent assay, and hemagglutination inhibition test with neutralization test for determination of immune status. J Clin Microbiol 1985; 22: 296-8.
24. Pedersen IR, Mordhorst CH, Ewald T, von Magnus H. Long-term antibody response after measles vaccination in an isolated arctic society in Greenland Vaccine 1986; 4: 173-8.
25. Peltola H, Heinonen OP. Frequency of true adverse reactions to measles-mumps-rubella vaccine: A double-blinded placebo-controlled trial in twins. Lancet 1986; 1: 939-42.
26. Peltola H, Heinonen OP, Valle M, et al The elimination of indigenous measles, mumps and rubella from Finland by a 12 year, two-dose vaccination program. N Engl J Med 1994; 331: 1397-402.
27. Plotkin S. Rubella vaccine. In: Plotkin SA, Mortirner EA, eds. Vaccines. Philadelphia: Saunders, 1994: pp 303-26.
28. Roberts RJ, Sandifer QD, Meiron RE, Nolan-Farrell MZ, Davis PM. Reasons for non-uptake of measles, mumps and rubella catch up immunization in a measles epidemic and side-effects of the vaccine. Br Med J 1995; 310: 1629-32.
29. Sakata H, Hishiyama M, Sugiura A. Enzyme-linked immunosorbent assay compared with neutralization tests for evaluation of live mumps vaccines. J Clin Microbiol 1984; 19: 21-5.
30. Samb B, Aaby P, Whittle HL, et al. Serologic status and measles attack rates among vaccinated and unvaccinated children in rural Senegal. Pediatr Infect Dis J 1995; 14: 203-09.
31. Schmitt HJS, Just M, Neiss A. Withdrawal of a mumps vaccine: reasons and impacts. Eur J Pedietr 1993; 152: 387-8.
32. Skendzel LP. Rubella immunity; Defining the level of protective antibody. Am J Clin Pathol 1996; 106: 170-4.
33. Takeuchi K, Tanabyashi K, Hishiyama M, Yamada A, Sugiura A. Variations of nucleotide sequences and transcription of the SH gene among mumps virus strains. Virology 1991; 181: 364-6.
34. Usonis V, Bakasenas V, Citour K, Clemens R. Comparative study of reactogenicity and immunogenicity of a new measles, mumps and rubella vaccine Priorix and M-M-R II in healthy children. Infection 1998; 26: 222-6.
35. Usonis V, Bakasenas V, Bock H, Chitour K, Clemens R. Reactogenicity and immunogenicity of a novel live attenuated combined measles, mumps and rubella vaccine in healthy children. Pediatr Infect Dis J 1999; 18: 42-8.
36. Weibel RE, Buynak EB, Mclean AA, Roehm RR, Hilleman MR. Persistence of antibody in human subjects for 7 to 10 years following administration of combined live attenuated measles, mumps and rubella virus vaccines (40967). Proc Soc Exp Biol Med 1980; 165: 260-3.
37. World Health Organisation (WHO): Expanded Program on Immunisation - accelerated measles strategies. Wkly Epidemiol Rec 1994; 69: 229-34.